Investigator(s): Keith Hoffman, PhD
Offers Additional Resources to Help its Startups Succeed
LOS ANGELES – (June 16, 2017) – LA BioMed is launching a Commercialization Accelerator Program™ (CAP), designed and implemented by Larta Institute, that will offer LA BioMed’s early stage bioscience companies additional resources to strengthen and speed their innovations to the marketplace, Keith B. Hoffman, PhD, LA BioMed vice president of business development and technology transfer, and Rohit Shukla, Larta Institute CEO, announced today.
Investigator(s): Jack Edwards Jr., MD
Dr. Edwards Receives the Rhoda Benham Award from Medical Mycology Society
“Congratulations to Dr. Edwards for this important recognition of his many accomplishments and contributions to this field of scientific study,” said David I. Meyer, PhD, LA BioMed president and CEO. “For more than three decades, Dr.
Investigator(s): The Lundquist Institute
Proceeds to Help Fund Institute’s Groundbreaking Research and New Facilities
LA BioMed and UCLA announced today that they have sold their royalty rights to Kybella®, the first and only FDA-approved injectable drug to treat submental fullness, that was originally developed by LA BioMed and UCLA researchers. Allergan, a global pharmaceutical company, is marketing Kybella® for the treatment of submental fullness.